

S 373

BENEFIT Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 23, 2021

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 23, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/373>

Sponsor

Name: Sen. Wicker, Roger F. [R-MS]

Party: Republican • **State:** MS • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Klobuchar, Amy [D-MN]	D · MN		Feb 23, 2021
Sen. Fischer, Deb [R-NE]	R · NE		Apr 13, 2021
Sen. Collins, Susan M. [R-ME]	R · ME		Mar 10, 2022

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 23, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 4472	Identical bill	Jul 19, 2021: Referred to the Subcommittee on Health.

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021

This bill requires the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Actions Timeline

- **Feb 23, 2021:** Introduced in Senate
- **Feb 23, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.